https://www.selleckchem.com/pr....oducts/apr-246-prima
029). The cumulative incidence of bacterial or fungal infections was significantly higher in the Induction group (HR 10.6, 95% CI 1.28-88.2, P=0.029). These results suggest that basiliximab-based induction therapy with delayed Tac initiation may suppress mild acute cellular rejection and improve renal function in recipients with renal dysfunction, resulting in its non-inferior outcome, even in high-risk patients, when applied to the appropriate recipients. However, it should be carefully considered in recipients at a high ris
Like
Comment
Share
